PRAMEF5

Across TCGA pan-cancer cohorts, PRAMEF5 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated PRAMEF5 data layer compared with 10 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher PRAMEF5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRAMEF5 expression acts as an unfavorable survival marker.

CESC are the cancer types where PRAMEF5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	All	0.140	0.823	<.001	24	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

PRAMEF5–CESC (DFS)

Open the CESC breakdown →